SCHEMBL17460171

SCHEMBL17460171

O=C(O)C=CCC(CC=CC(=O)O)c1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABBR2 O75899 2/20 0.44
GABBR1 Q9UBS5 2/20 0.44
HCAR2 Q8TDS4 3/20 0.43
CYP2D6 P10635 3/20 0.43
CYP2C19 P33261 2/20 0.43
CYP1A2 P05177 1/20 0.43
PKM P14618 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
HDAC3 O15379 1/20 0.42
TNKS O95271 1/20 0.42
HDAC4 P56524 1/20 0.42
HDAC1 Q13547 1/20 0.42
HDAC7 Q8WUI4 1/20 0.42
HDAC2 Q92769 1/20 0.42
HDAC10 Q969S8 1/20 0.42
HDAC11 Q96DB2 1/20 0.42
HDAC8 Q9BY41 1/20 0.42
TNKS2 Q9H2K2 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17730856 0.91 GABBR2 (0.41) GABBR2GABBR1HCAR2CYP2D6CYP2C19
SCHEMBL17730855 0.91 GABBR2 (0.41) GABBR2GABBR1HCAR2CYP2D6CYP2C19
SCHEMBL9380747 0.89 HCAR2 (0.42) GABBR2GABBR1HCAR2CYP2D6CYP2C19
SCHEMBL19899231 0.86 GABBR2 (0.41) GABBR2GABBR1HCAR2CYP2D6CYP2C19
SCHEMBL7238650 0.86 HCAR2 (0.44) HCAR2CYP2D6CYP2C19HDAC3TNKS
SCHEMBL3144362 0.86 HCAR2 (0.44) HCAR2CYP2D6CYP2C19HDAC3TNKS
SCHEMBL7239259 0.86 HCAR2 (0.44) HCAR2CYP2D6CYP2C19HDAC3TNKS
SCHEMBL17730949 0.81 CYP2C19 (0.62) HCAR2CYP2D6CYP2C19SMN1; SMN2HDAC3
SCHEMBL7374430 0.81 HCAR2 (0.49) HCAR2CYP2C19KDM4EMAPK1
SCHEMBL5744606 0.81 HCAR2 (0.45) GABBR2GABBR1HCAR2CYP2D6CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12629718-B2 Film forming method and article manufacturing method CANON KABUSHIKI KAISHA (JP) 2026-05-19 US disclosed
US-20260077385-A1 FILM FORMING METHOD, CURABLE COMPOSITION, AND ARTICLE MANUFACTURING METHOD CANON KABUSHIKI KAISHA (JP) 2026-03-19 US disclosed
US-20260042932-A1 COMPOSITION, PATTERN FORMING METHOD, AND ARTICLE MANUFACTURING METHOD CANON KK (JP) 2026-02-12 US disclosed
EP-4538019-A1 CURABLE COMPOSITION, METHOD FOR FORMING INVERTED PATTERN, METHOD FOR FORMING FILM, AND METHOD FOR PRODUCING ARTICLE CANON KABUSHIKI KAISHA (JP) 2025-04-16 EP disclosed
US-20250109253-A1 CURABLE COMPOSITION, INVERTED PATTERN FORMING METHOD, FILM FORMING METHOD, AND ARTICLE MANUFACTURING METHOD CANON KABUSHIKI KAISHA (JP) 2025-04-03 US disclosed
US-20250084270-A1 CURABLE COMPOSITION, FILM FORMING METHOD AND MANUFACTURING METHOD CANON KABUSHIKI KAISHA (JP) 2025-03-13 US disclosed
CN-119596642-A Curable composition, film forming method and manufacturing method 佳能株式会社 2025-03-11 CN disclosed
CN-119343746-A Curable composition, reverse pattern forming method, film forming method, and article manufacturing method 佳能株式会社 2025-01-21 CN disclosed
EP-4478398-A1 FILM FORMATION METHOD AND ARTICLE MANUFACTURING METHOD CANON KABUSHIKI KAISHA (JP) 2024-12-18 EP disclosed
US-20240392148-A1 PATTERN FORMING METHOD AND ARTICLE MANUFACTURING METHOD CANON KABUSHIKI KAISHA (JP) 2024-11-28 US disclosed
WO-2023243484-A1 CURABLE COMPOSITION, METHOD FOR FORMING INVERTED PATTERN, METHOD FOR FORMING FILM, AND METHOD FOR PRODUCING ARTICLE キヤノン株式会社 2023-12-21 WO disclosed
WO-2023162519-A1 PATTERN FORMING METHOD AND METHOD FOR PRODUCING ARTICLE キヤノン株式会社 2023-08-31 WO disclosed
WO-2023153123-A1 FILM FORMATION METHOD AND ARTICLE MANUFACTURING METHOD キヤノン株式会社 2023-08-17 WO disclosed
WO-2023112512-A1 FILM FORMING METHOD AND METHOD FOR PRODUCING ARTICLE キヤノン株式会社 2023-06-22 WO disclosed
CN-106574007-B Photocurable composition, method for producing pattern of cured product using same, method for producing optical component, and method for producing circuit board 佳能株式会社 2023-04-14 CN disclosed
WO-2022259748-A1 CURABLE COMPOSITION, FILM FORMATION METHOD, AND ARTICLE MANUFACTURING METHOD キヤノン株式会社 2022-12-15 WO disclosed
EP-3172247-B1 PHOTOCURABLE COMPOSITION, METHOD FOR PRODUCING CURED PRODUCT PATTERN USING THE SAME, METHOD FOR PRODUCING OPTICAL COMPONENT, AND METHOD FOR PRODUCING CIRCUIT BOARD CANON KK (JP) 2022-03-30 EP disclosed
US-20170210837-A1 PHOTOCURABLE COMPOSITION, METHOD FOR PRODUCING CURED PRODUCT PATTERN USING THE SAME, METHOD FOR PRODUCING OPTICAL COMPONENT, AND METHOD FOR PRODUCING CIRCUIT BOARD CANON KABUSHIKI KAISHA (JP) 2017-07-27 US disclosed
EP-3172247-A1 PHOTOCURABLE COMPOSITION, METHOD FOR PRODUCING CURED PRODUCT PATTERN USING THE SAME, METHOD FOR PRODUCING OPTICAL COMPONENT, AND METHOD FOR PRODUCING CIRCUIT BOARD Canon Kabushiki Kaisha (JP) 2017-05-31 EP disclosed
WO-2016013216-A1 PHOTOCURABLE COMPOSITION, METHOD FOR PRODUCING CURED PRODUCT PATTERN USING THE SAME, METHOD FOR PRODUCING OPTICAL COMPONENT, AND METHOD FOR PRODUCING CIRCUIT BOARD CANON KABUSHIKI KAISHA (JP) 2016-01-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260077385-A1 FILM FORMING METHOD, CURABLE COMPOSITION, AND ARTICLE MANUFACTURING METHOD EEF1D, RHOA, YWHAH GABBR2 3023/4885GABBR1 2829/4885HCAR2 4824/4885
US-20260042932-A1 COMPOSITION, PATTERN FORMING METHOD, AND ARTICLE MANUFACTURING METHOD SMCHD1, PIM1, PIM2 GABBR2 4003/4885GABBR1 4111/4885HCAR2 4882/4885
US-12629718-B2 Film forming method and article manufacturing method AUP1, VCL, RHOA GABBR2 2387/4885GABBR1 2048/4885HCAR2 4831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.